NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Mesothelioma and lung cancer are different conditions that can be caused by asbestos. Learn more about mesothelioma vs. lung ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...

ALTON The statistics surrounding the incidence rate of lung cancer nationally, state-wide, and locally can literally take your breath away.According to ...

A common malaria drug could be repurposed to treat a variety of hematologic cancers and solid tumors, according to early ...

Most people in the U.S. have received vaccines to protect against infectious diseases. A vaccine against smallpox led to the ...